News & Updates

Show Multimedia Only

Half of patients with EGFRm NSCLC on osimertinib-chemo alive at 4 years in FLAURA2

29 Sep 2025 by

In the planned final overall survival (OS) analysis of the FLAURA2 trial, first-line (1L) osimertinib plus chemotherapy significantly improved OS compared with osimertinib alone in EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC), supporting osimertinib as the backbone treatment in this setting.

Half of patients with EGFRm NSCLC on osimertinib-chemo alive at 4 years in FLAURA2

29 Sep 2025

Cisplatin-sparing toripalimab plus chemoradiotherapy feasible in advanced NPC

29 Sep 2025

Incorporating toripalimab into induction chemotherapy and radiotherapy without concurrent cisplatin appears to be efficacious and associated with low toxicity in patients with locoregionally advanced nasopharyngeal cancer (NPC), according to a phase III trial.

Cisplatin-sparing toripalimab plus chemoradiotherapy feasible in advanced NPC

29 Sep 2025

Oral bacteria, fungi linked to pancreatic cancer

28 Sep 2025

Oral microbiota, including bacteria and fungi, have emerged as risk factors for pancreatic cancer development in a recent study.

Oral bacteria, fungi linked to pancreatic cancer

28 Sep 2025

COVID-19 boosters shield cancer patients from severe disease

27 Sep 2025 by

Getting a COVID-19 booster shot yields significant protection against severe disease in patients with cancer, as shown in a large retrospective study.

COVID-19 boosters shield cancer patients from severe disease

27 Sep 2025

Evolving treatment landscape in R/R MM: Challenges and advances

27 Sep 2025 by

Treatment of relapsed or refractory multiple myeloma (R/R MM) remains challenging due to resistance to standard-of-care (SoC) therapies, leading to a poor prognosis. In an interview with MIMS Oncology, Dr Karen Hoi-Ki Tang, Specialist in Haematology & Haematological Oncology in Hong Kong, discussed unmet needs in managing R/R MM and the role of latest therapeutic options.

Evolving treatment landscape in R/R MM: Challenges and advances

27 Sep 2025

Eldecalcitol add-on therapy prevents bone loss in postmenopausal breast cancer patients

26 Sep 2025

The addition of eldecalcitol therapy to risedronate results in increased lumbar spine (LS) bone mineral density (BMD) in osteopenic to osteoporotic postmenopausal women with breast cancer who are receiving an aromatase inhibitor (AI), according to a study.

Eldecalcitol add-on therapy prevents bone loss in postmenopausal breast cancer patients

26 Sep 2025

Oral methylcobalamin eases hand-foot syndrome in breast cancer patients

26 Sep 2025 by

The use of oral methylcobalamin is effective in lessening the severity of hand-foot syndrome, without any serious safety concerns, among women with HER2 negative early breast cancer who are treated with adjuvant capecitabine, a study has shown.

Oral methylcobalamin eases hand-foot syndrome in breast cancer patients

26 Sep 2025

Nicotinamide delivers for skin cancer prevention

25 Sep 2025 by

Treatment with the over-the-counter vitamin B3 derivative nicotinamide can lower the risk of new skin cancers, and this risk reduction is greater for cutaneous squamous cell carcinoma and when treatment is initiated after the first skin cancer, according to a large retrospective study.

Nicotinamide delivers for skin cancer prevention

25 Sep 2025

Personalized risk messages improve CRC screening uptake

24 Sep 2025

A recent study has shown that the inclusion of personalized risk for advanced colorectal neoplasia (ACN) in a decision aid or provider notification provides no overall effect, but it has led to an increase in the uptake of stool testing in one health system.

Personalized risk messages improve CRC screening uptake

24 Sep 2025

Success factors in oncology drug development: Regional perspectives on amivantamab and NBTXR3

24 Sep 2025 by

At an industry-sponsored symposium during the European Society for Medical Oncology Targeted Anticancer Therapies Asia Congress (ESMO TAT Asia) 2025 in Hong Kong, regional experts reflected on pioneering oncology drug development. Dr Jii Bum Lee of Yonsei Cancer Center, Seoul, Republic of Korea, discussed the unique translational and clinical journey of amivantamab, an EGFR-MET bispecific antibody, which was first established as a treatment for non-small-cell lung cancer (NSCLC) with EGFR exon 20 insertion (exon20ins) mutations. Dr Herbert Loong of the Chinese University of Hong Kong shared the experience of advancing NBTXR3, a novel hafnium oxide–based nanoparticle radiosensitizer, into the clinic, underscoring the necessity of multidisciplinary collaboration for success.

Success factors in oncology drug development: Regional perspectives on amivantamab and NBTXR3

24 Sep 2025

News & Updates

Showing Oncology articles

Showing

Specialty:

Half of patients with EGFRm NSCLC on osimertinib-chemo alive at 4 years in FLAURA2

Half of patients with EGFRm NSCLC on osimertinib-chemo alive at 4 years in FLAURA2

Cisplatin-sparing toripalimab plus chemoradiotherapy feasible in advanced NPC

Cisplatin-sparing toripalimab plus chemoradiotherapy feasible in advanced NPC

Oral bacteria, fungi linked to pancreatic cancer

Oral bacteria, fungi linked to pancreatic cancer

COVID-19 boosters shield cancer patients from severe disease

COVID-19 boosters shield cancer patients from severe disease

Evolving treatment landscape in R/R MM: Challenges and advances

Evolving treatment landscape in R/R MM: Challenges and advances

Eldecalcitol add-on therapy prevents bone loss in postmenopausal breast cancer patients

Eldecalcitol add-on therapy prevents bone loss in postmenopausal breast cancer patients

Oral methylcobalamin eases hand-foot syndrome in breast cancer patients

Oral methylcobalamin eases hand-foot syndrome in breast cancer patients

Nicotinamide delivers for skin cancer prevention

Nicotinamide delivers for skin cancer prevention

Personalized risk messages improve CRC screening uptake

Personalized risk messages improve CRC screening uptake

Success factors in oncology drug development: Regional perspectives on amivantamab and NBTXR3

Success factors in oncology drug development: Regional perspectives on amivantamab and NBTXR3